Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lytixar (LTX-109) in uncomplicated Gram-positive skin infection
2010-021438-68Phase 2Completed
- Sponsor
- Lytix Biopharma
- Start
- Jul 2010
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Not applicable comparing Lytixar arm with Placebo arm (2 arms). Primary endpoint: Safety and local tolerability. Started Jul 2010; status: completed.
02
Drugs
voxvoganan
03
Conditions
Not applicable
Beyond the preview
Go deeper on 2010-021438-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021438-68.